FDA clears Medtronic Protecta ICDs, CRT-Ds
The FDA has approved Medtronic’s Protecta portfolio of implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy-defibrillators (CRT-Ds).
The new family of implantable defibrillators features SmartShock Technology, which includes six new Medtronic algorithms for arrhythmia recognition that deliver therapeutic shocks only when appropriate, according to the Minneapolis-based company. They include Wavelet + PR Logic, SVT discrimination in the VF zone and Confirmation; T-wave Discrimination and Lead Noise Discrimination; and Lead Integrity Alert, first released in 2008.
Shipments of the Protecta portfolio will begin immediately.
The new family of implantable defibrillators features SmartShock Technology, which includes six new Medtronic algorithms for arrhythmia recognition that deliver therapeutic shocks only when appropriate, according to the Minneapolis-based company. They include Wavelet + PR Logic, SVT discrimination in the VF zone and Confirmation; T-wave Discrimination and Lead Noise Discrimination; and Lead Integrity Alert, first released in 2008.
Shipments of the Protecta portfolio will begin immediately.